Ovarian cancer is the most common malignancy of the female genital tract. The age standardised death rate for ovarian cancer is steadily rising whereas the mortality for cervical cancer and endometrial cancer is falling, with that for breast cancer remaining unchanged (Beral, 1987) . Although the use of cisplatin or carboplatin has made some impact in the treatment of advanced epithelial ovarian cancer, the overall results remain disappointing (Neijt et al., 1987; Wiltshaw, 1985) . In particular platinum-containing regimens are associated with significant morbidity and may have an advelse affect on the quality of life. Measurability is also a problem in this disease. After primary debulking surgery many patients have small volume residual disease which cannot be measured by non-invasive means. In those cases where this residual disease is resistant to chemotherapy progression continues unnoticed whilst ineffective chemotherapy continues to be administered. In the absence of any new revolutionary therapy an alternative approach is the development of a prognosis orientated, patient adapted, treatment strategy. By the use of prognostic variables it may be possible to predict 'treatment failures' who are unlikely to benefit from current aggressive chemotherapy. Highly toxic and expensive therapy would therefore be restricted to those patients predicted to benefit.
The accepted clinicopathological factors of independent prognostic significance in epithelial ovarian cancer include age, International Federation of Obstetrics and Gynaecology (FIGO) stage, the amount of residual disease after primary surgery, performance status and histological grade (Neijt et al., 1987; Heintz et al., 1988; Malkasian et al., 1984; Voest et al., 1989) . The tumour associated antigen CA-125 is the most clinically useful serum tumour marker for epithelial ovarian cancer (Bast et al., 1983; Canney et al., 1984; Cruickshank et al., 1987) . It is an antigenic determinant defined by a murine IgGI monoclonal antibody raised against the serous ovarian carcinoma cell line OVCA 433 (Bast et al., 1981) . In advanced disease the reported sensitivity of pre-operative serum CA-125 approaches 100% and follow-up changes in serial CA-125 levels correlate with the clinical assessment of disease in 93% of instances (Bast et al., 1983; Cruickshank et (Cruickshank et al., 1987; Raju et al., 1987; Vergote et al., 1987; Lavin et al., 1987; Alvarez et al., 1987; Parker et al., 1988; Mobus et al., 1988; Van der Burg et al., 1988; Rustin et al., 1989; Hawkins et al., 1989; Redman et al., 1990) . These studies however have differences in their selected populations, prognostic endpoints and definitions of CA-125 characteristics examined.
The aim of this study was to use an independent data set to evaluate the relative clinical utility of a number of CA-125 parameters already shown to be of prognostic value in the published literature (Van der Burg et al., 1988; Rustin et al., 1989; Hawkins et al., 1989; Redman et al., 1990 ) within a defined clinical scenario -viz at some time prior to the third course of chemotherapy it is wished to distinguish reliably between treatment 'failures' and treatment 'successes'. A treatment failure is defined to be clinical progression or death within 12 months of starting chemotherapy; a success is taken to be a patient alive and progression free for at least 12 months. This is a definition designed for picking out candidates for stopping chemotherapy, for while a patient who dies or progresses within a year is clearly a failure the converse is not such a persuasive definition of success.
Materials and methods

Patients
Eighty-one patients with a diagnosis of epithelial ovarian cancer and a minimum of 1 years follow-up were used in this study. Forty-four patients were treated in Aberdeen (54%), 32 in Glasgow (40%) and five (6%) in Dundee. Thirty-six (41 %) were treated with either single agent cisplatin or carboplatin, 33 patients (41%) were treated with carboplatin/ chlorambucil or cisplatin/cyclophosphamide and a further 12 (15%) were treated with alkylating agents alone. All patients had initial debulking surgery, although for one patient the bulk of residual disease is not available; 54% of patients had residual disease >2 cm. The median age of the patients was 59 years (range 21-78, interquartile range 50-64). Other details of these patients are given in Table I. CA-125 assay CA-125 was measuired using the CIS-ELSA immunoradiometric assay [CIS (UK) Limited, High Wycombe, Buckinghamshire Table II. Statistical analysis Logistic regression (Cox, 1970) was used as the means of assessing the predictive value of variables. Log transformations were taken (to the base e) of all CA-125 measurements in order to improve the validity of the statistical methods used. Logged scales are also used to improve the clarity of the figures. CA-125 measurements below the detection limit of the assay (i.e. < 7 KU 1-') have been taken to be 3.5. The
McNemar test was used to compare the sensitivities of the prognostic indices at a fixed specificity.
Caveat
The fact that the three CA-125 measurements are available for all the patients in this paper means that they are not necessarily typical of the large number of patients treated with ovarian cancer at these institutions on whom all these measurements were not made. Some measurements are not taken because of early clinical progression, but the main reason is clinicians simply not requesting the assay for some patients. How different the distribution of the various prognostic indicators might be among failures and successes in these patients is a matter for speculation. There is no obvious reason to think that these distributions would be markedly different from those presented in the text and the general relevance of the results given rests on this assumption.
Results
Prognostic index I In the paper by Rustin et al., it is suggested that the change in CA-125 levels from before chemotherapy to 1 month later, after one course of chemotherapy could be used to divide patients into different prognostic groups. The best discrimination was found by splitting patients into those who showed a greater than 7-fold decrease in CA-125 levels and those who showed a smaller change.
The application of this criteria to our data is illustrated in Figure 1 . The data are plotted on a logged scale. The visible separation in the plot between successes and failures is statistically significant (P = 0.013 from logistic regression). The predictive value of using a greater than 7-fold drop to pick out successes if 74% (17/23); the predictive value of using less than a 7-fold drop to pick out failures is 57% (33/58). The sensitivity of this criteria for picking out treatment failures is 85% (33/39) and the specificity is 40% (17/42). The 7-fold cut-off is designed to pick out successes, but its effectiveness in doing so appears limited. Selecting a cut-off that just achieves a specificity of 90% for picking out treatment failures ((CA-125:2/CA-125:1) >0.81 or less than a 19% drop) results in a sensitivity of 31% (Table III) The results are presented in terms of the rate of change d loge (CA-125) from just before the first course of chemo therapy (CA-125: 1) to just before the third course of chemo therapy (CA-125:3)-this is log(1/2) times the reciprocal o the half-life. Again there is a statistically significant separa tion in this variable between the successes and the failure (P = 0.0008, from logistic regression). The point equivalen to a half-life of 20 days is indicated and using this to classif, patients as successes or failures would lead to a large amoun of misclassification. The predictive value of using this cut-of for picking out failures is 70% (28/40); for successes tho predictive values is 73% (30/41). The specificity of this cri teria for failures is 71% (30/42) and its sensitivity is 720' (28/39). Adjusting the cut-off to just obtain a specificit: >90% (rate of change > -0.009 or half-life >77 days results in a corresponding sensitivity of 31% (Table III) .
Comparison of indices at a fixed specificity The use of CA-125 for clinical decision making in epithelial ovarian cancer requires further investigation, both in determining and validating a prognostic index with acceptable misclassification rates, and in determining the clinical impact of treatment decisions made on the basis of such an index.
